Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) CEO Clarissa Sowemimo-Coker speaks to Proactive after the pharmaceutical group confirmed that she has now taken on the role on a permanent basis, having been appointed on an interim basis in December 2022.

Sowemimo-Coker highlights the ongoing work on four drug development programs, including awaiting approval from MHRA for the lead program targeting chemotherapy induced peripheral neuropathy.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com